Maridebart cafraglutide

卡格玛瑞德拜单抗

Report date: 2026/05/25 20:02:40
First In Class

Base Information

Drug NameMaridebart cafraglutide
Drug Alias NameMariTideAMG-133AMG133
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Antibody polypeptide conjugate (APC)
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor antagonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightBody WeightObesity +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen IncAmgen Biotechnology Consultation (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightBody WeightObesity +[9] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksWikipedia